[go: up one dir, main page]

Indari et al., 2022 - Google Patents

COVID-19 impact on host at pathophysiological and cellular level

Indari et al., 2022

View PDF
Document ID
4206342552526832104
Author
Indari O
Jakhmola S
Kashyap D
Baral B
Verma T
Jain K
Jha H
Publication year
Publication venue
Frontiers of COVID-19: Scientific and Clinical Aspects of the Novel Coronavirus 2019

External Links

Snippet

The COVID-19 pandemic has put millions of lives at risk. SARS-CoV-2, the causative agent of COVID-19, primarily targets the respiratory system. The subsequent immune reactions may cause severe inflammation. The severe infection, disease progression, and …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution

Similar Documents

Publication Publication Date Title
Lopes-Pacheco et al. Pathogenesis of multiple organ injury in COVID-19 and potential therapeutic strategies
Najafloo et al. Mechanism of anosmia caused by symptoms of COVID-19 and emerging treatments
Xian et al. Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation
Battagello et al. Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission
Atri et al. COVID-19 for the cardiologist: basic virology, epidemiology, cardiac manifestations, and potential therapeutic strategies
Ganji et al. Impact of COVID-19 on mitochondrial-based immunity in aging and age-related diseases
Ferren et al. Hamster organotypic modeling of SARS-CoV-2 lung and brainstem infection
Srinivasan et al. Roles of host mitochondria in the development of COVID-19 pathology: could mitochondria be a potential therapeutic target?
Choudhary et al. Insights of severe acute respiratory syndrome coronavirus (SARS-CoV-2) pandemic: a current review
Zhou et al. Bioengineered neutrophil extinguisher targets cascade immune pathways of macrophages for alleviating cytokine storm in pneumonia
Garcia-del-Barco et al. Revisiting pleiotropic effects of type I interferons: rationale for its prophylactic and therapeutic use against SARS-CoV-2
Harris et al. The multifaceted roles of NLRP3-modulating proteins in virus infection
Yates et al. Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness
Carvajal et al. New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic
US20230104343A1 (en) Cxcr4 inhibitor for the treatment of acute respiratory distress syndrome and viral infections
Chen et al. The immune mechanism of the nasal epithelium in COVID-19–related olfactory dysfunction
Dezfuli et al. Update on immunology of COVID-19 disease and potential strategy for controlling
AL-SALIH et al. Identify Human Cluster of differentiation 147 (CD147), a New Target of SARS-CoV-2 Invasion.
Golota et al. Pathogenesis of the initial stages of severe COVID-19
Sahoo et al. Paradigm of immune dysregulation in coronavirus disease-2019 infection
Indari et al. COVID-19 impact on host at pathophysiological and cellular level
Kao et al. Negative regulation of type I interferon signaling by integrin-linked kinase permits dengue virus replication
Zhang et al. Local complement contributes to pathogenic activation of lung endothelial cells in SARS-CoV-2 infection
Saceleanu et al. SARS-COV-2–the pandemic of the XXI century, clinical manifestations–neurological implications
Rodrigues et al. Inflammasome Activation by RNA Respiratory Viruses: Mechanisms, Viral Manipulation, and Therapeutic Insights